FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: genetic testing
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Cancer risks of people with inherited PALB2 mutations
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: people with inherited PALB2 mutations
In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women considering breastfeeding who have inherited BRCA mutations.
Data from a large-scale study suggests that breastfeeding may protect against ovarian cancer in women with inherited mutations in BRCA1 or BRCA2. (1/28/21)
Este artículo está disponible en español.
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Inherited gene mutations found in pancreatic cancer families in Spain
Relevance: Medium
Strength of Science: Medium
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with pancreatic cancer and a family history of pancreatic or other cancers
This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Young women with, or at high risk for an inherited BRCA mutation
Inherited mutations in the BRCA1 and BRCA2 genes are linked to a high lifetime risk of breast and other cancers. This study shows that women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. (10/26/20)
Read MoreStudy : Among women with breast cancer, who should have genetic testing for an inherited mutation?
Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer
Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)
Read MoreUpdate : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer
Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)
The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : What is the risk for a new breast cancer diagnosis in the other breast for women with a BRCA1, BRCA2 or TP53 mutation?
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Women diagnosed with breast cancer who have a mutation in BRCA1, BRCA2 or TP53
For women who have been diagnosed with breast cancer, knowing their risk of breast cancer in the other (contralateral) breast can help them make decisions about surgery and screening. This study shows that women with an inherited mutation in BRCA1, BRCA2 or TP53 have an increased risk for contralateral breast cancer. This risk is highest in women with a TP53 mutation. (6/6/20)
Read MoreStudy : Racial and ethnic differences in genetic testing among young breast cancer survivors
Most relevant for: Women diagnosed with breast cancer at age 50 or younger
Genetic testing is recommended for most women who are diagnosed with breast cancer at age 50 or younger. In this study of young women with breast cancer, while the rates of genetic testing did not differ, the rates of women testing positive for an inherited mutation associated with breast cancer did vary between racial and ethnic groups. (2/27/20)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Cancer risk associated with inherited mutations in Lynch syndrome genes
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with Lynch syndrome mutations
Lynch syndrome is the most common inherited cause of cancer affecting about 1 in 300 people. People with Lynch syndrome have an increased risk of colorectal endometrial and other cancers. A large study followed people with mutations in the Lynch syndrome genes MLH1, MSH2, MSH6 and PMS2 to determine the risk of other types of cancer. (2/21/20)
Read More